This was shown by Mori et al. [53], who investigated the OATP1B1/3 inhibition potency of paclitaxel in therapeutic doses in patients with non-small cell lung cancer by assessing changes in the plasma concentrations of multiple endogenous biomarkers of OATP1B1/3, including CPI, CPIII, sulfate-conjugated bile acids, and glucuronide-conjugated bile acids. This evidence concerns the gene SLCO1B1 and non-small cell lung carcinoma.